Vincerx Pharma, Inc.
VINC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1,068 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $270 |
| Gross Profit | $0 | $534 | $0 | -$270 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $1,018 | $3,268 | $3,908 | $3,754 |
| G&A Expenses | $2,316 | $5,558 | $3,885 | $3,612 |
| SG&A Expenses | $2,316 | $5,558 | $3,885 | $3,612 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,334 | $8,826 | $7,793 | $7,366 |
| Operating Income | -$3,334 | -$8,826 | -$7,793 | -$7,366 |
| % Margin | – | -826.4% | – | – |
| Other Income/Exp. Net | -$1,666 | $832 | -$50 | $5,558 |
| Pre-Tax Income | -$5,000 | -$7,994 | -$7,843 | -$1,808 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,000 | -$7,994 | -$7,843 | -$1,808 |
| % Margin | – | -748.5% | – | – |
| EPS | -0.96 | 4.22 | -1.41 | -0.32 |
| % Growth | -122.7% | 399.3% | -340.6% | – |
| EPS Diluted | -0.96 | 4.22 | -1.41 | -0.32 |
| Weighted Avg Shares Out | 5,234 | 5,234 | 5,568 | 5,568 |
| Weighted Avg Shares Out Dil | 5,234 | 5,234 | 5,568 | 5,568 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $62 | $154 | $157 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $281 | $275 | $270 |
| EBITDA | -$3,334 | -$8,545 | -$7,518 | -$7,096 |
| % Margin | – | -800.1% | – | – |